Submit an Article
Navigate
Home
Editorial Board
Editorial Policies
Current Volume
Archive
Scientific Integrity
Publication Ethics Statements
Interviews with Outstanding Authors
Newsroom
Sponsored Conferences
Podcast
Contact
Special Collections
Submit an Article
Online ISSN: 1945-4589
Review
|
Volume 10, Issue 12
|
pp. 4248–4268
How I treat elderly patients with plasma cell dyscrasias
Back to article
Figure 2
(2 of 3)
−
100%
+
Figure 2.
Recommendations for the treatment of previously treated patients with Waldenstrom’s Macroglobulinemia.
Figure adjusted from ESMO guidelines for WM 2018 and EMN recommendations for treatment of rare plasma cell dyscrasias. R: rituximab.
